AGM/EGMMay 20, 2026, 04:08 PM
Inovio Stockholders Approve Directors, Auditor, Incentive Plan
AI Summary
Inovio Pharmaceuticals, Inc. held its 2026 Annual Meeting of Stockholders, where shareholders approved all four proposals, including the election of eight director nominees, the ratification of Ernst & Young LLP as the independent auditor, the advisory approval of executive compensation, and the amendment and restatement of the 2023 Omnibus Incentive Plan. Concurrently, the Board of Directors approved immediate amendments to the company's bylaws to enhance corporate governance, clarifying the Chairman's role and establishing a Lead Independent Director position.
Key Highlights
- Board approved immediate amendments to bylaws to enhance corporate governance practices.
- Bylaws clarify the Chairman's role and establish a Lead Independent Director position.
- Annual Meeting had 58.57% of common stock present or represented by proxy.
- Stockholders elected eight director nominees to serve until the 2027 Annual Meeting.
- Appointment of Ernst & Young LLP as independent auditor was ratified with 39,329,582 votes For.
- Non-binding advisory approval of NEO compensation received 21,500,999 votes For.
- Amendment and restatement of the 2023 Omnibus Incentive Plan was approved with 21,559,350 votes For.
Price Impact
More from INO